1. Nicolas Giguère et al., “On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson’s Disease,” Frontiers in Neurology 9 (June 2018), e00455, https://doi.org/10.3389/fneur.2018.00455.
2. “Statistics,” Understanding Parkinson’s, Parkinson’s Foundation, accessed January 2, 2020, https://www.parkinson.org/Understanding-Parkinsons/Statistics.
3. IOS Press, “Emerging Evidence of an Impending Parkinson’s Disease Pandemic Identified,” ScienceDaily, January 29, 2019, https://www.sciencedaily.com/releases/2019/01/190129124853.htm.
4. Ibid.
5. “Parkinson’s Disease,” Patients, Conditions, Parkinson’s Disease, UCB Canada, accessed December 9, 2019, https://www.ucb-canada.ca/en/Patients/Conditions/Parkinson-s-Disease; “Statistics About Parkinson’s,” Parkinson’s Australia, accessed December 9, 2019, https://www.parkinsons.org.au/statistics; “The Incidence and Prevalence of Parkinson’s in the UK: Results From the Clinical Practice Research Datalink Reference Report,” Parkinson’s UK, last reviewed January 5, 2018, https://www.parkinsons.org.uk/professionals/resources/incidence-and-prevalence-parkinsons-uk-report.
6. Parkinson’s 101,” About Parkinson’s, The Michael J. Fox Foundation for Parkinson’s Research, accessed December 9, 2019, https://www.michaeljfox.org/parkinsons-101.
7. “What is Early Onset Parkinson’s Disease?” What is Parkinson’s Disease, American Parkinson Disease Association, accessed December 9, 2019, https://www.apdaparkinson.org/what-is-parkinsons/early-onset-parkinsons-disease/.
8. Stephen K. Van Den Eeden et al., “Incidence of Parkinson’s Disease: Variation by Age, Gender, and Race/Ethnicity,” American Journal of Epidemiology 157, no. 11 (June 2003): 1015–22, https://doi.org/10.1093/aje/kwg068.
9. Ibid.
10. Nicolas Giguère et al., “Increased Vulnerability of Nigral Dopamine Neurons After Expansion of Their Axonal Arborization Size Through D2 Dopamine Receptor Conditional Knockout,” PLoS Genetics 15, no. 8 (August 2019), e1008352, https://doi.org/10.1371/journal.pgen.1008352.
11. “Types of Parkinson’s and Parkinsonism,” Drug-Induced Parkinsonism, European Parkinson’s Disease Association, last reviewed September 2018, https://www.epda.eu.com/about-parkinsons/types/drug-induced-parkinsonism/.
12. Ibid.
13. J. William Langston, “The MPTP Story,” Journal of Parkinson’s Disease 7, no. 1 (March 2017): S11–19, https://doi.org/10.3233/JPD-179006.
14. “Environmental Factors,” Understanding Parkinson’s, Parkinson’s Foundation, accessed December 9, 2019, https://www.parkinson.org/Understanding-Parkinsons/Causes/Environmental-Factors.
15. “Parkinson’s Genetics,” Causes, The Michael J. Fox Foundation for Parkinson’s Research, accessed December 9, 2019, https://www.michaeljfox.org/news/parkinsons-genetics.
16. Ibid.
17. Caroline M. Tanner et al., “Rotenone, Paraquat, and Parkinson’s Disease,” Environmental Health Perspectives 119, no. 6 (June 2011), https://doi.org/10.1289/ehp.1002839.
18. S. Jafari et al., “Head Injury and Risk of Parkinson’s Disease: a Systematic Review and Meta-Analysis,” Movement Disorders 28, no. 9 (August 2013), https://doi.org/10.1002/mds.25458.
19. Brad A. Racette et al., “Dose-Dependent Progression of Parkinsonism in Manganese-Exposed Welders,” Neurology 88, no. 4 (January 2017), https://doi.org/10.1212/WNL.0000000000003533.
20. Bert M. Verheijen, Kiyomitsu Oyanagi, and Fred W. van Leeuwen, “Dysfunction of Protein Quality Control in Parkinsonism—Dementia Complex of Guam,” Frontiers in Neurology 9, no. 173 (March 2018), https://doi.org/10.3389/fneur.2018.00173.
21. E. Rivadeneyra-Domínguez and J. F. Rodríguez-Landa, “Cycads and Their Association With Certain Neurodegenerative Diseases,” Neurología (English Edition) 29, no. 9 (November–December 2014): 517–22, https://doi.org/10.1016j.nrleng.2013.03.005.
22. Stephen M. Bloomfield, “Parkinson-Plus Syndromes,” Neurology, Medscape, updated September 24, 2018, https://emedicine.medscape.com/article/1154074-overview#a4.
23. Joseph Jankovic, “Distinguishing Essential Tremor from Parkinson’s Disease,” Practical Neurology (November/December 2012), https://practicalneurology.com/articles/2012-nov-dec/distinguishing-essential-tremor-from-parkinsons-disease/pdf.
24. “Young-Onset Parkinson’s Disease,” About Parkinson’s, The Michael J. Fox Foundation for Parkinson’s Research, accessed December 9, 2019, https://www.michaeljfox.org/news/young-onset-parkinsons-disease.
25. “Tremor in Parkinson’s,” Symptoms of Parkinson’s, American Parkinson Disease Association, accessed December 9, 2019, https://www.apdaparkinson.org/what-is-parkinsons/symptoms/tremor/.
26. Ibid.
27. Wenbow Zhou, Jessica Cummiskey Barkow, and Curt R. Freed, “Running Wheel Exercise Reduces α-Synuclein Aggregation and Improves Motor and Cognitive Function in a Transgenic Mouse Model of Parkinson’s Disease,” PLoS ONE 12, no. 12 (December 2017), https://doi.org/10.1371/journal.pone.0190160.
28. Mark F. Lew, “Rasagiline Treatment Effects on Parkinsonian Tremor,” International Journal of Neuroscience 123, no. 12 (December 2013): 859–65, https://doi.org/10.3109/00207454.2013.812085.
29. Clifford W. Shults et al., “Effects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline,” Archives of Neurology 59, no. 10 (October 2002): 1541–50, https://doi.org/10.1001/archneur.59.10.1541.
30. “Coenzyme Q10 Strikes Out in Phase 3 for Parkinson’s,” News, AlzForum, March 31, 2014, https://www.alzforum.org/news/research-news/coenzyme-q10-strikes-out-phase-3-parkinsons.
31. Xiang Gao et al., “Prospective Study of Dietary Pattern and Risk of Parkinson’s Disease,” American Journal of Clinical Nutrition 86, no. 5 (November 2007): 1486–94.
32. M. D. Benedetti et al., “Smoking, Alcohol, and Coffee Consumption Preceding Parkinson’s Disease: A Case-Control Study,” Neurology 55, no. 9 (November 2000): 1350–58, https://doi.org/10.1212/WNL.55.9.1350.
33. “Tremor in Parkinson’s,” Symptoms of Parkinson’s, American Parkinson Disease Association, accessed December 9, 2019, https://www.apdaparkinson.org/what-is-parkinsons/symptoms/tremor/.
34. Rachel Dolhun, “Ask the MD: Pain and Parkinson’s Disease,” The Michael J. Fox Foundation for Parkinson’s Research, February 22, 2017, https://www.michaeljfox.org/news/ask-md-pain-and-parkinsons-disease/.
35. “Depression: Overview and Its Role in Parkinson’s Disease,” Health Library, Disease and Conditions, Cleveland Clinic, last reviewed September 30, 2015, https://my.clevelandclinic.org/health/diseases/9379-depression-overview-and-its-role-in-parkinsons-disease.
36. “Amoxapine,” MedFacts, Drugs.com, last updated July 1, 2019, https://www.drugs.com/cdi/amoxapine.html.
37. Marina Maffoni et al., “Stigma Experienced by Parkinson’s Disease Patients: A Descriptive Review of Qualitative Studies,” Parkinsons Disease 2017 (January 2017): 1–7, e7203259, https://doi.org/10.1155/2017/7203259.
38. Ana Sandoiu, “Parkinson’s Drugs May Lead to Compulsive Behavior,” Medical News Today, June 21, 2018, https://www.medicalnewst.oday.com/articles/322197.php.
39. “Speech and Swallowing,” Swallowing and Dental Challenges, Parkinson’s Foundation, accessed December 9, 2019, https://www.parkinson.org/speech-swallowing-library.
40. “Sleep Disorders in Parkinson’s Disease: Diagnosis and Management,” Annals of Indian Academy of Neurology 14, suppl. 1 (July 2011): S18–20, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152169/.
41. Anindita Bose, G. A. Petsko, and D. Eliezer, “Parkinson’s Disease and Melanoma: Co-occurrence and Mechanisms,” Journal of Parkinson’s Disease 8, no. 3 (August 2018): 385–98. https://doi.org/10.3233/JPD-171263.
42. “Depression: Overview and Its Role in Parkinson’s Disease,” Health Library, Disease and Conditions, Cleveland Clinic, last reviewed September 30, 2015, https://my.clevelandclinic.org/health/diseases/9379-depression-overview-and-its-role-in-parkinsons-disease.
43. Peter A. LeWitt et al., “The Efficacy Profile of Rotigotine During the Waking Hours in Patients With Advanced Parkinson’s Disease: A Post Hoc Analysis,” Clinical Neuropharmacology 39, no. 2 (March/April 2016): 88–93, https://doi.org/10.1097/WNF.0000000000000133.
44. Frederick. L. Hitti et al., “Long-Term Outcomes Following Deep Brain Stimulation for Parkinson’s Disease,” Journal of Neurosurgery 18 (January 2019): 1–6, https://doi.org/10.3171/2018.8.JNS182081.
45. Daniel Waldvogel et al., “Beware of Deep Water After Subthalamic Deep Brain Stimulation,” American Academy of Neurology (November 27, 2019), https://doi.org/10.1212/WNL.0000000000008664.
46. Diksha Mohanty and Steven Lippmann, “Marijuana for Parkinson’s Disease?” Innovations in Clinical Neuroscience 16, no. 1–2 (January 2019): 33–34, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC 6450681/.
47. Rachel Dolhun, “Ask the MD: Medical Marijuana and Parkinson’s Disease,” The Michael J. Fox Foundation for Parkinson’s Research, October 2, 2019, https://www.michaeljfox.org/news/ask-md-medical-marijuana-and-parkinsons-disease.
48. “Emerging Research Highlights Potential Benefits of Glutathione Supplements for Parkinson’s Disease,” Foundational Medicine Review, accessed December 9, 2019, https://www.foundational medicinereview.com/blog/emerging-research-highlights-potential-benefits-of-glutathione-supplements-for-parkinsons-disease/.
49. Rachel Dolhun, “Ask the MD: Glutathione and Parkinson’s,” The Michael J. Fox Foundation for Parkinson’s Research, November 24, 2015, https://www.michaeljfox.org/news/ask-md-glutathione-and-parkinsons.
50. Robert Cilia et al., “Mucuna Pruriens in Parkinson Disease: A Double-Blind, Randomized, Controlled, Crossover Study,” Neurology 89, no. 5 (August 2017). https://doi.org/10.1212/WNL.0000000000004175.
51. Miguel A. Hernán et al., “Cigarette Smoking and the Incidence of Parkinson’s Disease in Two Prospective Studies,” Annals of Neurology 50, no. 6 (December 2001): 780–86, https://doi.org/10.1002/ana.10028; Xiao Li et al., “Association Between Cigarette Smoking and Parkinson’s Disease: A Meta-Analysis,” Archives of Gerontology and Geriatrics 61, no. 3 (November–December 2015): 510–16, https://doi.org/10.1016/j.archger.2015.08.004; Eilis J. O’Reilly et al., “Smokeless Tobacco Use and the Risk of Parkinson’s Disease Mortality,” Movement Disorders 20, no. 10 (October 2005): 1383–84, https://doi.org/10.1002/mds.20587.
52. Miguel A. Hernán et al., “A Meta-Analysis of Coffee Drinking, Cigarette Smoking, and the Risk of Parkinson’s Disease,” Annals of Neurology 52, no. 3 (September 2002): 276–84, https://doi.org/10.1002/ana.10277; Beate Ritz et al., “Pooled Analysis of Tobacco Use and Risk of Parkinson Disease,” Archives of Neurology 64, no. 7 (July 2007): 990–97, https://doi.org/10.1001/archneur.64.7.990; Susan Searles Nielson et al., “Environmental Tobacco Smoke and Parkinson’s Disease,” Movement Disorders 27, no. 2 (February 2012): 293–97, https://doi.org/10.1002/mds.24012.
53. Rachel Dolhun, “Nicotine Patch Not Beneficial in Parkinson’s, The Michael J. Fox Foundation for Parkinson’s Research, October 8, 2018, https://www.michaeljfox.org/news/nicotine-patch-not-beneficial-parkinsons?nicotine-patch-not-beneficial-in-parkinson=.
54. Susan Searles Nielson et al., “Nicotine From Edible Solanaceae and Risk of Parkinson Disease,” Annals of Neurology 74, no. 3 (September 2013): 472–77, https://doi.org/10.1002/ana.23884.
55. “Parkinson’s Disease Dementia,” Types of Dementia, Alzheimer’s Association, accessed December 9, 2019, https://www.alz.org/alzheimers-dementia/what-is-dementia/types-of-dementia/parkinson-s-disease-dementia.
56. “Possible Interactions With: Vitamin B6 (Pyridoxine),” Health Information Library, Milton S. Hershey Medical Center, Penn State Hershey, accessed December 9, 2019, http://pennstatehershey.adam.com/content.aspx?productId=107&pid=33&gid=000992.
57. Mario Caruana, Ruben Cauchi, and Neville Vassallo, “Putative Role of Red Wine Polyphenols Against Brain Pathology in Alzheimer’s and Parkinson’s Disease,” Frontiers in Nutrition 3 (August 2016), https://doi.org/10.3389/fnut.2016.00031.
58. Honor Whiteman, “How Caffeine Could Help Slow Parkinson’s Disease,” Medical News Today, October 3, 2016, https://www.med icalnewstoday.com/articles/313241.php; Natalia Palacios et al., “Caffeine and Risk of Parkinson Disease in a Large Cohort of Men and Women,” Movement Disorders 27, no. 10 (September 2012): 1276–82, https://doi.org/10.1002/mds.25076.
59. Natalia Palacios et al., “Caffeine and Risk of Parkinson Disease in a Large Cohort of Men and Women,” Movement Disorders 27, no. 10 (September 2012): 1276–82, https://doi.org/10.1002/mds.25076.
60. Tommaso Schirinzi et al., “Dietary Vitamin E as a Protective Factor for Parkinson’s Disease: Clinical and Experimental Evidence,” Frontiers in Neurology 10 (February 2019): 148, https://doi.org/10.3389/fneur.2019.00148.
61. Joanna Kocot et al., “Does Vitamin C Influence Neurodegenerative Diseases and Psychiatric Disorders?” Nutrients 9, no. 7 (July 2017). https://doi.org/10.3390/nu9070659.
62. E. F. dos Santos et al., “Evidence That Folic Acid Deficiency Is a Major Determinant of Hyperhomocysteinemia in Parkinson’s Disease,” Metabolic Brain Disease 24, no. 2 (June 2009): 257–69. https://doi.org/10.1007/s11011-009-9139-4; S. Zoccolella et al., “Elevated Homocysteine Levels in Parkinson’s Disease: Is There Anything Besides L-Dopa Treatment?” Current Medicinal Chemistry 17, no. 3 (2010): 213–21, https://doi.org/10.2174/092986710790149774.
63. Arne Reimers and Hanna Ljung, “The Emerging Role of Omega-3 Fatty Acids as Therapeutic Option in Neuropsychiatric Disorders,” Therapeutic Advances in Psychopharmacology 9 (June 24, 2019), https://doi.org/10.1177/2045125319858901.
64. J. Kehr et al., “Ginkgo Biloba Leaf eEtract (EGb 761®) and Its Specific Acylated Flavonol Constituents Increase Dopamine and Acetylcholine Levels in the Rat Medial Prefrontal Cortex: Possible Implications for the Cognitive Enhancing Properties of EGb 761,” International Psychogeriatrics 24, S1 (August 2012), https://doi.org/10.1017/S1041610212000567; K. Blecharz-Klin et al., “Pharmacological and Biochemical Effects of Ginkgo Biloba Extract on Learning, Memory Consolidation and Motor Activity in Old Rats,” Acta Neurobiologiae Experimentalis 69, no. 2 (2009): 217–31, https://www.ncbi.nlm.nih.gov/pubmed/19593336.
65. Neha Sharma and Bimla Nehru, “Curcumin Affords Neuroprotection and Inhibits α-Synuclein Aggregation in Lipopolysaccharide-Induced Parkinson’s Disease Model,” Inflammopharmacology 26, no. 2 (April 2018): 349–60, https://doi.org/10.1007/s10787-017-0402-8.
66. Babita Singh et al., “Role of Ethanolic Extract of Bacopa Monnieri Against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Induced Mice Model via Inhibition of Apoptotic Pathways of Dopaminergic Neurons,” Brain Research Bulletin 135 (October 2017): 120–28, https://doi.org/10.1016/j.brainresbull.2017.10.007.
67. Kasi P. Devi et al., “A Mini Review on the Chemistry and Neuroprotective Effects of Silymarin,” Current Drug Targets 18, no. 13 (2017): 1529–36, https://doi.org/10.2174/138945011766 6161227125121.
68. Hammad Ullah and Haroon Khan, “Anti-Parkinson Potential of Silymarin: Mechanistic Insight and Therapeutic Standing,” Frontiers in Pharmacology 9 (2018), https://doi.org/10.3389/fphar.2018.00422.
69. Stacey E. Seidl et al., “The Emerging Role of Nutrition in Parkinson’s Disease,” Frontiers in Aging Neuroscience 6 (March 7, 2014), https://doi.org/10.3389/fnagi.2014.00036.
70. E. Olsson et al., “Abstract: Milk, Yogurt, and Soured Milk Consumption and Risk of Parkinson’s Disease,” Uppsala University, Symposium 68: Nutrition, March 31, 2019, accessed December 9, 2019, https://cmoffice.kenes.com/cmsearchableprogrammeV15/conferencemanager/programme/personid/anonymous/adpd19/normal/b833d15f547f3cf698a5e922754684fa334885ed#!abstr actdetails/0000228940; American Academy of Neurology, “Does Consuming Low-Fat Dairy Increase the Risk of Parkinson’s Disease?” Medical Press, Parkinson’s and Movement Disorders, June 7, 2017, https://medicalxpress.com/news/2017-06-consuming-low-fat-dairy-parkinson-disease.html.
71. P. Humphries, E. Pretorius, and H. Naudé, “Direct and Indirect Cellular Effects of Aspartame on the Brain,” European Journal of Clinical Nutrition 62 (April 2007): 451–62, https://doi.org/10.1038/sj.ejcn.1602866
72. Rebecca Gilbert, “What We Know About Avoiding Particular Foods and Supplements for Parkinson’s,” Living With Parkinson’s, American Parkinson Disease Association, April 22, 2019, https://www.apdaparkinson.org/article/nutrition-and-parkinsons-disease-part-one/.
73. Zehra Kazmi et al., “Monosodium Glutamate: Review on Clinical Reports,” International Journal of Food Properties 20, no. 2 (December 2017): 1807–15, https://doi.org/10.1080/10942912.2017.1295260.
74. “Parkinson’s Outcomes Project,” Parkinson’s Foundation, accessed December 29, 2019, https://www.parkinson.org/research/Parkinsons-Outcomes-Project.
75. Shannon Robalino et al., “Effectiveness of Interventions Aimed at Improving Physical and Psychological Outcomes of Fall-Related Injuries in People With Dementia: A Narrative Systematic Review,” Systematic Reviews 7 (2018), e31, https://doi.org/10.1186/s13643-018-0697-6; “Choosing Wisely: Physical Restraints,” American Academy of Nursing (2015), Rev. 10/14, https://www.aannet.org/initiatives/choosing-wisely/physical-restraints.
76. “Parkinson’s Disease Dementia,” Types of Dementia, Alzheimer’s Association, accessed December 9, 2019, https://www.alz.org/alzheimers-dementia/what-is-dementia/types-of-dementia/parkinson-s-disease-dementia.
77. “What Is Lewy Body Dementia?” Health Information, National Institute on Aging, U.S. Department of Health and Human Services, reviewed June 27, 2018, https://www.nia.nih.gov/health/what-lewy-body-dementia.
78. Susan Schneider Williams, “The Terrorist Inside My Husband’s Brain,” Neurology 87, no. 13 (September 2016): 1308–11, https://doi.org/10.1212/WNL.0000000000003162.